Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma
Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma
复制标题
DOI：
10.1016/j.urolonc.2017.02.008
复制
发表时间：
2017-06-01
影响因子：
2.7
通讯作者：
Xu, Jiejie
中科院分区：
文献类型：
--
作者：
Liu, Yidong;Liu, Zheng;Xu, Jiejie
目的：半乳糖凝集素-9是“串联重复”型半乳糖凝集素的一员，与β -半乳糖苷具有亲和力，在各种肿瘤的免疫调节、生存和生长中发挥重要作用。本研究旨在揭示半乳糖凝集素-9在膀胱尿路上皮癌（UCB）术后的临床意义。材料和方法：我们回顾性纳入2002年至2014年在同一研究所接受根治性膀胱切除术的202例UCB患者。组织微阵列免疫组化检测半乳糖凝集素-9的表达。Kaplan-Meier法绘制生存曲线。通过整合多变量Cox分析的无复发生存期（RFS）和癌症特异性生存期（CSS）的所有独立指标，构建预后nomogram。此外，我们评估了半乳糖凝集素-9表达升高或降低的患者是否可以从辅助化疗中获益。结果：半凝集素-9低表达与淋巴血管侵犯（P = 0.002）、早期复发（P = 0.010）、短CSS （P = 0.002）相关。此外，多变量分析发现半乳糖凝集素-9表达是RFS（风险比= 0.62;95% CI: 0.40 0.95; P = 0.030）和CSS（风险比= 0.46;95% CI: 0.26-0.81; P = 0.008）的潜在独立指标。此外，半凝集素-9低患者的辅助化疗获益优于半凝集素-9高患者（P = 0.014）。结论：半乳糖凝集素-9的表达是UCB患者RFS和CSS的独立预后因素。半凝集素-9表达的评估可以预测辅助化疗的获益。(C) 2017爱思唯尔公司版权所有。
Purpose: Galectin-9, a member of the "tandem repeat" type galectins performing as animal lectins with an affinity for beta-galactosides, has been well documented to exert crucial functions in immunomodulation, survival, and growth of various tumors. This study aims to reveal the clinical significance of galectin-9 in urothelial carcinoma of the bladder (UCB) postoperatively.Materials and methods: We retrospectively included 202 patients with UCB who underwent radical cystectomy at a single institute from 2002 to 2014. Galectin-9 expression was assessed by immunohistochemistry on tissue microarrays. The Kaplan-Meier method was conducted to plot survival curves. Prognostic nomograms were constructed via integrating all the independent indicators from multivariate Cox analysis for recurrence-free survival (RFS) and cancer-specific survival (CSS). In addition, we evaluate whether patients with increased or decreased galectin-9 expression might benefit from adjuvant chemotherapy.Results: Low galectin-9 expression was significantly correlated with lymphovascular invasion (P = 0.002), early recurrence (P = 0.010), and short CSS (P = 0.002). Furthermore, multivariate analysis identified galectin-9 expression as a potential independent indicator for RFS (hazard ratio = 0.62; 95% CI: 0.40 0.95; P = 0.030) and CSS (hazard ratio = 0.46; 95% CI: 0.26-0.81; P = 0.008). Moreover, the benefit associated with adjuvant chemotherapy was superior among galectin-9 low patients than among galectin-9 high patients (P = 0.014).Conclusions: Expression of galectin-9 is an independent prognostic factor for RFS and CSS in patients with UCB. Evaluation of galectin-9 expression may predict the benefit from adjuvant chemotherapy. (C) 2017 Elsevier Inc. All rights reserved.